GLP1R and obesity due to melanocortin 4 receptor deficiency: It must be noted that glucagon-like peptide-1 receptor (GLP-1R) agonists, approved to treat obesity, elicit robust improvements in overweight, and provide cardioprotection in individuals at risk of or with pre-existing cardiovascular disease [102].